Skip to main content

Table 1 Summary of cancer drugs in this review

From: Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer

Rapamycin analogues Known target Disease
 Temsirolimus mTOR Renal cell carcinoma
 Ridaforolimus (formerly known as Deforolimus) mTOR Breast cancer
Soft tissue sarcoma
Head and neck cancer
Non-small cell lung cancer
   Colorectal cancer
 Everolimus mTOR Hormone receptor positive, HER2 negative breast cancer
Inhibitors/Antibodies   
 Letrozole Competitive inhibitor of aromatase Breast cancer
 Tamoxifen Antagonist of estrogen receptor Breast cancer
 Trastuzumab HER2 receptor Breast cancer
 Aromasin Aromatase inhibitor Hormone receptor positive, HER2 negative breast cancer
 Lapatinib EGFR HER2 positive breast cancer